期刊文献+

阿苯达唑抑制P-糖蛋白表达对耐顺铂卵巢癌细胞耐药性的影响 被引量:4

Albendazole reverses chemoresistance of cisplatin-resistant ovarian cancer cells by inhibiting P-glycoprotein expression
下载PDF
导出
摘要 目的探讨阿苯达唑(albendazole,ABZ)通过抑制人耐顺铂卵巢癌SKOV-3/DDP细胞P-糖蛋白(P-glycopro-tein,P-gp)的表达对细胞耐药性的影响。方法在体外,用溴化二甲噻唑二苯四氨唑(MTT)比色法检测ABZ对SKOV-3/DDP细胞增殖的影响,求得抑制率为0%、25%、50%、75%所对应的ABZ浓度,并按抑制率将实验分为对照组,25%抑制浓度(IC25)组、半数抑制浓度(IC50)组和75%抑制浓度(IC75)组,每组给予相应浓度的ABZ处理,并按作用时间再将每组分为12、24、36 h亚组。分别用流式细胞仪检测各组细胞表面P-gp的表达。将不同浓度的顺铂(cisplatin,DDP)、表阿霉素(epirubicin,EPI)、5-氟尿嘧啶(5-fluorouracil,5-Fu)按照分组,联合和序贯ABZ处理细胞后,采用MTT比色法检测SKOV-3/DDP细胞体外增殖情况。结果 ABZ作用SKOV3/DDP细胞后使P-gp表达下降,呈浓度和时间依赖性。联合和序贯ABZ均能降低DDP、EPI和5-Fu对SKOV-3/DDP细胞的作用浓度,有浓度和时间依赖性,且联合作用优于序贯作用。结论在体外ABZ通过抑制SKOV-3/DDP细胞P-gp表达提高细胞对DDP、EPI、5-Fu的敏感性,并能逆转细胞的耐药性。 Objective To investigate the effect of albendazole(ABZ) on the chemoresistance of cisplatin-resistant human ovarian cancer SKOV-3/DDP cells by inhibiting P-glycoprotein(P-gp) expression.Method The effect of ABZ on the proliferation of SKOV-3/DDP cells was detected by methyl thiazolyl tetrazolium(MTT) colorimetry.According to the inhibition concentrations(IC) of 0%,25%,50% and 75%,the cells were then divided into 4 groups including a control group,an IC25 group,an IC50 group and an IC75 group.Moreover,each group was divided into three subgroups(12,24 and 36 h) based on the ABZ treatment time.P-gp expression was determined by flow cytometry.The proliferation of SKOV-3/DDP cells was detected by MTT colorimetry after the treatment with ABZ combined and sequential with cisplatin(DDP),epirubicin(EPI) and 5-fluorouracil(5-Fu).Results The expression of P-gp was decreased by ABZ in a dose-and time-dependent manner.Both combined and sequential with ABZ could decrease the effective concentrations of DDP,EPI and 5-Fu to SKOV-3/DDP cells in a dose-and time-dependent manner,and the effect of combination was better than that of sequential treatment.Conclusion Through down-regulating the expression of P-gp in SKOV-3/DDP cells,ABZ can increase the sensitivity of SKOV-3/DDP cell to DDP,EPI and 5-Fu,and reverse its chemoresistance.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第17期1762-1765,共4页 Journal of Third Military Medical University
关键词 阿苯达唑 P-糖蛋白 耐药性 albendazole P-glycoprotein chemoresistance
  • 相关文献

参考文献15

  • 1Siegel R, Naishadham D, Jemal A Cancer J Clin, 2012, 62(1) : 10 - Cancer Statistics, 2012 [ J]. CA 29.
  • 2Bast R C Jr, Hennessy B, Mills G B. The biology of ovarian cancer: new opportunities for translation [ J ]. Nat Rev Cancer, 2009, 9 (6) : 415 -428.
  • 3Kawakami Y, Miyamoto K, Takehara K, et al. Down-regulation of MDR1 by epigenetic alteration in human epithelial ovarian cancer cells[J]. J Clin Oncol, 2009, 27(Suppl) : e16556.
  • 4Bell D R, Gerlach J H, Kartner N, et al. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with muhidrug resist- ance[J]. J Clin Oncol, 1985, 3(3) : 311 -315.
  • 5Pourgholami M H, Woon L, Almajd R, et al. In vitro and in vivo sup- pression of growth of hepatocellular carcinoma cells by albendazole [ J ]. Cancer Lett, 2001, 165 (1) : 43 -49.
  • 6Khalilzadeh A, Wangoo K T, Morris D L, et al. Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways [ J ]. Biochem Pharmacol, 2007, 74 (3) : 407 -414.
  • 7Chu S W, Badar S, Morris D L, et al. Potent inhibition of tubulin po- lymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole [ J ]. Anticancer Res, 2009, 29 (10) : 3791 -3796.
  • 8LI Qing-zhang HAO Yan-hong GAO Xue-jun GAO Wen-xue ZHAO Bing.The Target of Benzimidazole Carbamate Against Cysticerci cellulosae[J].Agricultural Sciences in China,2007,6(8):1009-1017. 被引量:4
  • 9Lacey E, Watson T R. Activity of benzimidazole carbamates against L1210 mouse leukaemia ceils: correlation with in vitro tubulin polymer- ization assay[ J ]. Bioehem Pharmacol, 1985, 34 (19) : 3603 - 3605.
  • 10Pourgholami M H, Cai Z Y, Badar S, et al. Potent inhibition of tu- moral hypoxia-inducible factor 1 alpha by albendazole [ J ]. BMC Canc- er, 2010, 10: 143.

二级参考文献16

  • 1高学军,李庆章,刘永洁,郝艳红.奥芬达唑和阿苯达唑对猪囊尾蚴作用形态学比较观察[J].中国兽药杂志,2004,38(8):9-12. 被引量:5
  • 2高学军,李庆章.苯并咪唑氨基甲酸酯类抗蠕虫药物作用机理研究进展[J].东北农业大学学报,2004,35(4):492-495. 被引量:14
  • 3Liu Y J,Li Q Z,Hao Y H.Morphological changes to earlystage Cysticerci cellulosae cysticerci following oxfendazoletreatmant[].The Veterinary Journal.2003
  • 4McCracken R O,Lipkowitz K B.Structure-activityrelationships of benzimidazole and benzothiazoleanthelmintics: a molecular modeling approach to in vivo drugefficacy[].Journal of Parasitology.1990
  • 5Menzel R,Rodel M,Kulas J,Steinberg C E.CYP35:xenobiotically induced gene expression in the nematodeCaenorhabditis elegans[].Archives of Biochemistry andBiophysics.2005
  • 6Merino G,Jonker J W,Wagenaar E,Pulido M M,Molina A J,Alvarez A I,Schinkel A H.Transport of anthelminticbenzimidazole drugs by breast cancer resistance protein(BCRP/ABCG2)[].Drug Metabolism and Disposition: theBiological Fate of Chemicals.2005
  • 7Oh S J,,Park J,Lee M J,Park S Y,Lee J H,Choi K.Ecological hazard assessment of major veterinarybenzimidazoles: acute and chronic toxicities to aquaticmicrobes and invertebrates[].Environmental Toxicology andChemistry.2006
  • 8Pushker N,Bajaj M S,Balasubramanya R.Disseminatedcysticercosis involving orbit, brain and subcutaneous tissue[].The Journal of Infection.2005
  • 9Takayanagui O M,Odashima N S.Clinical aspects of neurocysticercosis[].Parasitology International.2006
  • 10Vanden B H.Studies of the mode of action of anthelminticdrugs: tools to investigate the biochemical peculiarities ofhelminthes[].Annales de Parasitologie Humaine et Comparée.1990

共引文献3

同被引文献74

  • 1柳士忠,王恩波,许林.希土元素1:12系列杂多配合物的氧化还原性和稳定性质研究[J].无机化学学报,1994,10(1):40-46. 被引量:7
  • 2Ziebarth AJ, Landen C NJr, Alvarez R D. Molecularl genetic thera-pies in ovarian cancer: future opportunities and challenges[J]. Clin Obstet Gynecol, 2012, 55 (1 ) : 156 -172.
  • 3Hernandez-Vargas H, PalaciosJ, Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines[J]. Cell Cycle, 2007 , 6 (7) : 780 - 783.
  • 4MackeyJ R, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10- year follow-up of the phase 3 randomised BCIRG 001 triall L]. Lancet Oncol, 2013, 14(1): 72 - 80.
  • 5Lattanzio L, Tonissi F, Monteverde M, et al. Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells[J]. Anticancer Drugs, 2013, 24( 2) : 120 - 130.
  • 6Garcia A A, Yessaian A, Pham H, et al. Phase II study of gemcit-abine and docetaxel in recurrent platinum resistant ovarian cancer[J] . Cancer Invest, 2012, 30(4): 295 -299.
  • 7Nakamura T, Fuwa N, Takayama K, et al. Phase I study of weekly do-cetaxel and cisplatin arterial infusion for recurrent head and neck cane-er[J]. Head Neck, 2012, 34(11): 1634 -1639.
  • 8Komiyama K, Kobayashi K, Minezaki S, et al. Phase I I II trial of a biweekly combination of S-I plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG'{)601 )[J]. BrJ Cancer, 2012, 107 (9) : 1474 -1480.
  • 9Berns EM, Bowtell D D. The changing view of high-grade serous ovar-ian cancer[J]. Cancer Res, 2012, 72(11): 2701-2704.
  • 10De-Souza R, Zahedi P, Moriyama E H, et al. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer] J]. Mol Cancer Ther, 2010, 9( 6) : 1820 -1830.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部